CAR extracellular domain engineering provides specificity for anti-tumor effects, such as anti-CD123 targeting acute myeloid leukemia cells16, anti-CD19 targeting B cell lymphoma17, and anti-CD70 for hematological malignancies and solid tumors18. The gene discussed is CD19; the disease is neoplasm.